Skip to main content
. 2024 Mar 13;16(3):e56105. doi: 10.7759/cureus.56105

Figure 3. Therapeutic target diversity among novel disease-modifying treatments.

Figure 3

The image showing the therapeutic target diversity among novel disease modifying treatments (DMTs) recently approved by the United States Food and Drug Administration, or that are in phase 3 of clinical trials. The illustration was originally created by the authors.